---
title: Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
nct_id: NCT07166003
overall_status: RECRUITING
sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
study_type: OBSERVATIONAL
primary_condition: Lung Cancer, Non-Small Cell
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07166003.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07166003"
ct_last_update_post_date: 2025-09-10
last_seen_at: "2026-05-12T06:16:14.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer

**Official Title:** Effects of Neoadjuvant Immunotherapy on Patients With Lung Cancer: a Prospective, Observational Study

**NCT ID:** [NCT07166003](https://clinicaltrials.gov/study/NCT07166003)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 500
- **Lead Sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Conditions:** Lung Cancer, Non-Small Cell, Immunotherapy
- **Start Date:** 2025-04-20
- **Completion Date:** 2030-04-14
- **CT.gov Last Update:** 2025-09-10

## Brief Summary

The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are:

* Does pneumonectomy bring more benefits for pateints than lobectomy?
* Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.

## Detailed Description

This observational study aims to comprehensively evaluate the effectiveness and long-term clinical outcomes of neoadjuvant treatment in patients with lung cancer. Central to this investigation are two key questions: ·Does pneumonectomy bring more benefits for pateints than lobectomy?

* Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment, and through rigorous analysis of data, this study endeavors to provide nuanced insights into these fundamental queries, fostering advancements in clinical decision-making and patient management strategies.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 79 Years
- **Sex:** ALL

```
Inclusion Criteria:

1. Aged between 18 and 79 years;
2. Received at least two cycles of neoadjuvant immunotherapy;
3. ECOG performance status score of 0;
4. Complete clinical information including imaging data available.

Exclusion Criteria:

1. Diagnosed with or suspected active autoimmune diseases;
2. Presence of EGFR/ALK sensitive mutations;
3. Pregnant or breastfeeding women;
4. Previous anti-tumor therapies including chemotherapy or radiotherapy;
5. History of organ transplantation or hematopoietic stem cell transplantation;
6. Interstitial pneumonia, pulmonary fibrosis, or severe emphysema;
7. Uncontrolled diabetes mellitus;
8. Uncontrolled hypertension.
```

## Arms

- **Surgery** — Patients will undergo surgery after neoadjuvant immunotherapy.
- **Non-surgery** — Patients will receive non-surgical treatment after neoadjuvant treatment.

## Interventions

- **Pneumonectomy** (PROCEDURE) — Patients will receive pneumonectomy after neoadjuvant treatment
- **lobectomy** (PROCEDURE) — Patients will receive lobectomy after neoadjuvant immunotherapy.
- **radiotherapy** (RADIATION) — Patients will receive radiotherapy after neoadjuvant immunotherapy.
- **Anti-Tumor Drugs** (DRUG) — Patients will receive anti-tumor drugs.

## Primary Outcomes

- **Event-free survival** _(time frame: Event-free survival was defined as the time from neoadjuvant treatment to metastasis or death by any cause in the absence of metastasis, up to approximately 10 years.)_

## Secondary Outcomes

- **Overall survival** _(time frame: From date of neoadjuvant treatment until date of death due to any cause, up to approximately 10 years.)_
- **Perioperative Complication rate** _(time frame: Within 6 months after neoadjuvant treatment.)_

## Locations (1)

- Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.cancer hospital chinese academy of medical sciences|beijing||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07166003.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07166003*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*